Invention Grant
- Patent Title: Cyclopropylamines as LSD1 inhibitors
-
Application No.: US15708270Application Date: 2017-09-19
-
Publication No.: US10064854B2Publication Date: 2018-09-04
- Inventor: Neil W. Johnson , Jiri Kasparec
- Applicant: GlaxoSmithKline Intellectual Property (No.2) Limited
- Applicant Address: GB Brentford, Middlesex
- Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
- Current Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
- Current Assignee Address: GB Brentford, Middlesex
- Agent Duke M. Fitch; Kathryn A. Lutomski; Edward R. Gimmi
- Main IPC: A61K31/445
- IPC: A61K31/445 ; C07D401/12 ; C07F5/02 ; C07D211/26 ; C07D401/04 ; C07D265/30 ; C07C211/36 ; C07D211/62 ; C07D401/06 ; C07C271/24 ; C07D413/06 ; C07C211/35 ; C07D211/96 ; C07F9/59 ; C07D223/04 ; C07D207/09 ; C07D401/10
Abstract:
This invention relates to the use of cyclopropylamine derivatives for the modulation, notably the inhibition of the activity of Lysine-specific demethylase 1 (LSD1). Suitably, the present invention relates to the use of cyclopropylamines in the treatment of cancer.
Public/Granted literature
- US20180000805A1 CYCLOPROPYLAMINES AS LSD1 INHIBITORS Public/Granted day:2018-01-04
Information query
IPC分类:
